AstraZeneca buys biopharmaceutical company Fusion

To accelerate the development of next-generation radioconjugates to treat cancer

AstraZeneca to acquire Amolyt Pharma

Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition

Syngene biologics facility to be operational for US, European customers from mid-year

New facility includes 20KL of single use drug substance capacity coupled with drug product filling capacity of up to one million vials per day

Bayer and Aignostics to collaborate on next generation precision oncology

Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development

CuraTeQ Biologics announces the successful Phase 1 clinical study outcome of their BP11 product

Jubilant Ingrevia partners with O2 Renewable to increase use of green energy

This partnership marks a significant step for the Company towards establishing renewable energy power generation using hybrid open excess through solar and wind sources

European Commission approves Pfizer’s Prevenar 20 to help protect infants and children against pneumococcal disease

PREVENAR offers the broadest serotype coverage of any pediatric pneumococcal conjugate vaccine to help protect infants and children from the 20 serotypes responsible for the majority of currently circulating pneumococcal disease in the EU and globally

Successful use of Zidebactam/Cefepime to treat skull bone infection & pneumonia caused by extreme-drug resistant pseudomonas

With just few days of treatment, the patient started responding well and finally complete clinical resolution of infection was attained

USFDA grants orphan drug and pediatric exclusivities for Cresemba for aspergillosis and mucormycosis in children

CRESEMBA receives seven years and six months of US market exclusivity for these pediatric indications

AbCellera and Biogen collaborate on neurological antibody therapy

AbCellera will receive an upfront payment and is eligible to receive additional milestone payments